| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| R01 Fund LP | 45% | +181% | $74,228,505 | +$72,707,353 | 56,806,080 | +4780% | R01 Fund LP | 16 Oct 2025 |
| Framework Ventures IV L.P. | 45% | +181% | $74,228,505 | +$72,707,353 | 56,806,080 | +4780% | Framework Ventures IV L.P. | 16 Oct 2025 |
| Lazar David E. | 20% | 0% | $2,002,723 | +$402,699 | 1,502,080 | +25% | David E. Lazar | 16 Oct 2025 |
| POPLAR POINT CAPITAL MANAGEMENT LLC | 18% | 0% | $1,360,366 | 1,020,300 | 0% | Poplar Point Capital Management LLC | 15 Oct 2025 |
As of 30 Sep 2025, 13 institutional investors reported holding 226,659 shares of NovaBay Pharmaceuticals, Inc. - Common Stock, $0.01 par value (NBY). This represents 0.18% of the company’s total 125,955,831 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 226,659 | $289,925 | +$135,650 | $1.28 | 13 |
| 2025 Q2 | 218,522 | $126,743 | -$84,498 | $0.58 | 12 |
| 2025 Q1 | 362,238 | $211,908 | +$113,243 | $0.58 | 15 |
| 2024 Q4 | 167,029 | $100,725 | +$22,013 | $0.60 | 14 |
| 2024 Q3 | 125,970 | $87,462 | +$79,538 | $0.69 | 12 |
| 2024 Q2 | 11,501 | $25,420 | +$25,420 | $2.24 | 7 |